I4909
Ifosfamide
≥98%
Synonym(s):
Ifex, N,3-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine-2-oxide
Sign Into View Organizational & Contract Pricing
All Photos(3)
About This Item
Empirical Formula (Hill Notation):
C7H15Cl2N2O2P
CAS Number:
Molecular Weight:
261.09
EC Number:
MDL number:
UNSPSC Code:
41116107
PubChem Substance ID:
NACRES:
NA.25
Recommended Products
Quality Level
Assay
≥98%
shipped in
wet ice
storage temp.
2-8°C
SMILES string
ClCCNP1(=O)OCCCN1CCCl
InChI
1S/C7H15Cl2N2O2P/c8-2-4-10-14(12)11(6-3-9)5-1-7-13-14/h1-7H2,(H,10,12)
InChI key
HOMGKSMUEGBAAB-UHFFFAOYSA-N
Looking for similar products? Visit Product Comparison Guide
Application
- Ewing sarcoma of the pancreas: a pediatric case report and narrative literature review: This study explores the effectiveness of Ifosfamide in the treatment of rare pediatric Ewing sarcoma of the pancreas, providing valuable insights into the chemotherapeutic management of rare cancers (Liu et al., 2024).
- Prognostic value of hemogram parameters in osteosarcoma: The French OS2006 experience: Highlights the role of Ifosfamide in osteosarcoma treatment as part of a clinical trial, evaluating its impact on survival rates and treatment outcomes (Bastard et al., 2024).
- Case report: Characteristics and nature of primary cardiac synovial sarcoma: Discusses the utilization of Ifosfamide in managing primary cardiac synovial sarcoma, with an emphasis on its pharmacodynamics and therapeutic efficacy (Kawasaki et al., 2024).
- Dedifferentiated liposarcoma of the spermatic cord: Examines Ifosfamide′s mechanism of action in treating dedifferentiated liposarcoma, contributing to the broader understanding of its application in sarcoma therapy (Panther et al., 2024).
- A Rare Case of Extranodal Natural Killer/T-cell Lymphoma, Nasal Type Associated With Hemophagocytic Lymphohistiocytosis in a Patient With Recurrent Sinusitis: This article details the clinical use of Ifosfamide in treating aggressive lymphoma, underscoring its role in complex cases where standard treatments may not suffice (Christensen et al., 2024).
Biochem/physiol Actions
Ifosfamide is a nitrogen mustard compound that is a structural isomer of cyclophosphamide. Ifosfamide is a prodrug that must be transformed by cytochrome P450 to the biologically active component. It is used as an antineoplastic agent in cancer chemotherapy, but ifosfamide is more likely to cause renal toxicity than cyclophosphamide.
Signal Word
Danger
Hazard Statements
Precautionary Statements
Hazard Classifications
Acute Tox. 3 Oral - Carc. 1B - Eye Irrit. 2 - Muta. 1B - Repr. 1B
Storage Class Code
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Personal Protective Equipment
dust mask type N95 (US), Eyeshields, Gloves
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Customers Also Viewed
Andrea B Apolo et al.
Journal of the National Cancer Institute, 105(7), 499-503 (2013-02-16)
A prognostic model that predicts overall survival (OS) for metastatic urothelial cancer (MetUC) patients treated with cisplatin-based chemotherapy was developed, validated, and compared with a commonly used Memorial Sloan-Kettering Cancer Center (MSKCC) risk-score model. Data from 7 protocols that enrolled
Evaristus C Mbanefo et al.
Scientific reports, 9(1), 1586-1586 (2019-02-09)
Ifosfamide and other oxazaphosphorines can result in hemorrhagic cystitis, a constellation of complications caused by acrolein metabolites. We previously showed that a single dose of IPSE (Interleukin-4-inducing principle from Schistosoma eggs), a schistosome-derived host modulatory protein, can ameliorate ifosfamide-related cystitis;
Cecile Faure-Conter et al.
Pediatric blood & cancer, 61(2), 253-259 (2013-08-14)
Some children with extracranial germ cell tumors (GCT) relapse after or do not respond to first-line treatment combining chemotherapy and surgery, of whom very few experience long-term survival despite multimodal salvage treatment. This prospective study, part of the French TGM95
S Stacchiotti et al.
European journal of cancer (Oxford, England : 1990), 49(10), 2376-2383 (2013-04-10)
To report on anthracycline-based chemotherapy in a retrospective case-series analysis of solitary fibrous tumour (SFT) patients treated within the Italian Rare Cancer Network. We reviewed a set of SFT treated with chemotherapy since 2002, focusing on anthracycline, administered alone or
M Tiseo et al.
British journal of cancer, 108(8), 1695-1703 (2013-04-04)
The FAST was a factorial trial in first-line treatment of advanced non-small-cell lung cancer (NSCLC), addressing the role of replacing cisplatin with a non-platinum agent. The prognostic and predictive effect of ERCC1/BRCA1 expression and ERCC1/XPD/XRCC1-3 gene polymorphisms on outcomes of
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service